Qeen Biotechnologies
A private biotech delivering GMP‑grade bacteriophage therapeutics and manufacturing services across human, animal, and agricultural markets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A private biotech delivering GMP‑grade bacteriophage therapeutics and manufacturing services across human, animal, and agricultural markets.
Human Infectious DiseasesVeterinary Infectious DiseasesAgricultural Plant PathogensAquaculture Infectious DiseasesNutraceuticals
Technology Platform
Isolation, engineering, and GMP‑compliant high‑titer production of lytic bacteriophages with proprietary formulation and quality control processes for multi‑sector applications.
Opportunities
Strategic alliances with pharma and agri‑tech firms to co‑develop phage therapeutics, and expansion into regulatory‑approved commercial products could drive significant revenue growth.
Risk Factors
Regulatory uncertainty for bacteriophage biologics and competition from emerging proprietary phage platforms may limit market penetration.
Competitive Landscape
Key competitors include Adaptive Phage Therapeutics, Locus Biosciences, and AmpliPhi Biosciences; Qeen differentiates through its end‑to‑end GMP manufacturing services and multi‑industry focus.